🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Manidipine 20mg

    Takeda

    Hypertension

    approved small molecule terminated

    1 trial

  2. Maribavir

    Takeda

    Transplant Complication

    approved small molecule completed

    1 trial

  3. Metformin

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  4. Midodrine HCl

    Takeda

    Orthostatic Hypotension

    approved small molecule completed

    1 trial

  5. Midodrine HCl

    Takeda

    Symptomatic Orthostatic Hypotension

    approved small molecule completed

    1 trial

  6. Midodrine Hydrochloride

    Takeda

    Hypotension, Orthostatic

    approved small molecule completed

    2 trials

  7. Mixed amphetamine salts (ADDERALL XR)

    Takeda

    ADHD

    approved small molecule completed

    1 trial

  8. NESINA ACT TAB. 25/15mg

    Takeda

    Diabetes

    approved small molecule active

    1 trial

  9. Naltrexone HCl/Bupropion HCl Placebo

    Takeda

    Weight Regain Post Bariatric Surgery

    approved small molecule terminated

    1 trial

  10. Niraparib

    Takeda

    Epithelial Ovarian Cancer

    approved small molecule active

    1 trial

  11. Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]

    Takeda

    Hemophilia A

    approved mab completed

    2 trials

  12. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease

    approved small molecule completed

    2 trials

  13. Pantoprazole

    Takeda

    Gastroesophageal Reflux

    approved small molecule completed

    3 trials

  14. Pioglitazone

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule completed

    2 trials

  15. Pioglitazone

    Takeda

    Diabetes Type 2

    approved small molecule completed

    1 trial

  16. Pioglitazone

    Takeda

    Bone Metabolism

    approved small molecule completed

    1 trial

  17. Pioglitazone

    Takeda

    Metabolic Syndrome

    approved small molecule completed

    1 trial

  18. Pioglitazone

    Takeda

    Nonalcoholic Steatohepatitis

    approved small molecule completed

    1 trial

  19. Pioglitazone

    Takeda

    Obesity

    approved small molecule completed

    1 trial

  20. Pioglitazone

    Takeda

    Type II Diabetes Mellitus

    approved small molecule completed

    1 trial

  21. Pioglitazone

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    9 trials

  22. Pioglitazone 15mg

    Takeda

    Inflammation

    approved small molecule completed

    1 trial

  23. Pioglitazone and insulin

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    2 trials

  24. Pioglitazone and metformin

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    5 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources